Literature DB >> 22311616

Experimental human influenza: observations from studies of influenza antivirals.

Frederick G Hayden1.   

Abstract

Randomized, placebo-controlled trials have been conducted for nearly five decades in experimentally induced human influenza infections to assess the effectiveness, tolerability and pharmacological properties of influenza antivirals. The results of such studies have not only provided key proof-of-concept data to facilitate drug development but also contributed to our understanding of influenza pathogenesis and transmission. The lack of availability of contemporary, safety-tested virus inoculation pools in recent years needs to be resolved in order to avoid hindering the development of new drugs and vaccines.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22311616     DOI: 10.3851/IMP2062

Source DB:  PubMed          Journal:  Antivir Ther        ISSN: 1359-6535


  16 in total

Review 1.  Malaria medicines: a glass half full?

Authors:  Timothy N C Wells; Rob Hooft van Huijsduijnen; Wesley C Van Voorhis
Journal:  Nat Rev Drug Discov       Date:  2015-05-22       Impact factor: 84.694

2.  Validation of the wild-type influenza A human challenge model H1N1pdMIST: an A(H1N1)pdm09 dose-finding investigational new drug study.

Authors:  Matthew J Memoli; Lindsay Czajkowski; Susan Reed; Rani Athota; Tyler Bristol; Kathleen Proudfoot; Sarah Fargis; Matthew Stein; Rebecca L Dunfee; Pamela A Shaw; Richard T Davey; Jeffery K Taubenberger
Journal:  Clin Infect Dis       Date:  2014-11-20       Impact factor: 9.079

3.  Reply to Bernstein, Atmar, and Hoft.

Authors:  Alison Han; Jeffery K Taubenberger; Matthew J Memoli
Journal:  Clin Infect Dis       Date:  2020-12-31       Impact factor: 9.079

4.  Reply to Hunsberger and Memoli, "Efficacy Analysis in Healthy-Volunteer Influenza Challenge Trials: Intention To Treat".

Authors:  Jacqueline M McBride; Jeremy J Lim; Tracy Burgess; Rong Deng; Michael A Derby; Mauricio Maia; Priscilla Horn; Omer Siddiqui; Daniel Sheinson; Haiyin Chen-Harris; Elizabeth M Newton; Dimitri Fillos; Denise Nazzal; Carrie M Rosenberger; Maikke B Ohlson; Rob Lambkin-Williams; Hosnieh Fathi; Jeffrey M Harris; Jorge A Tavel
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

5.  Efficacy Analysis in Healthy-Volunteer Influenza Challenge Trials: Intention To Treat.

Authors:  Sally Hunsberger; Matthew J Memoli
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

Review 6.  Amantadine and rimantadine for influenza A in children and the elderly.

Authors:  Márcia G Alves Galvão; Marilene Augusta Rocha Crispino Santos; Antonio J L Alves da Cunha
Journal:  Cochrane Database Syst Rev       Date:  2014-11-21

7.  Safety and Efficacy of CR6261 in an Influenza A H1N1 Healthy Human Challenge Model.

Authors:  Alison Han; Lindsay Czajkowski; Luz Angela Rosas; Adriana Cervantes-Medina; Yongli Xiao; Monica Gouzoulis; Keith Lumbard; Sally Hunsberger; Susan Reed; Rani Athota; Holly Ann Baus; Amy Lwin; Jerald Sadoff; Jeffery K Taubenberger; Matthew J Memoli
Journal:  Clin Infect Dis       Date:  2021-12-06       Impact factor: 9.079

Review 8.  Influenza prevention and treatment in transplant recipients and immunocompromised hosts.

Authors:  Michael G Ison
Journal:  Influenza Other Respir Viruses       Date:  2013-11       Impact factor: 4.380

9.  Evaluation of oseltamivir prophylaxis regimens for reducing influenza virus infection, transmission and disease severity in a ferret model of household contact.

Authors:  Ding Yuan Oh; Sue Lowther; James M McCaw; Sheena G Sullivan; Sook-Kwan Leang; Jessica Haining; Rachel Arkinstall; Anne Kelso; Jodie Mcvernon; Ian G Barr; Deborah Middleton; Aeron C Hurt
Journal:  J Antimicrob Chemother       Date:  2014-05-19       Impact factor: 5.790

10.  Accelerating Influenza Research: Vaccines, Antivirals, Immunomodulators and Monoclonal Antibodies. The Manufacture of a New Wild-Type H3N2 Virus for the Human Viral Challenge Model.

Authors:  Daniel J Fullen; Nicolas Noulin; Andrew Catchpole; Hosnieh Fathi; Edward J Murray; Alex Mann; Kingsley Eze; Ganesh Balaratnam; Daryl W Borley; Anthony Gilbert; Rob Lambkin-Williams
Journal:  PLoS One       Date:  2016-01-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.